Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538045 | 0.90 | IMPDH2 (0.43) | ALDH1A1CYP2C19MAPTMEN1CYP1A2 | |
| SCHEMBL538405 | 0.88 | MAPT (0.39) | ALDH1A1CYP2C19MAPTMEN1CYP1A2 | |
| SCHEMBL20150583 | 0.85 | MEN1 (0.57) | ALDH1A1CYP2C19MAPTMEN1CYP1A2 | |
| SCHEMBL1467162 | 0.85 | GABRA1 (0.48) | ALDH1A1CYP2C19MAPTMEN1CYP1A2 | |
| SCHEMBL15161635 | 0.85 | ALDH1A1 (0.41) | ALDH1A1CYP2C19MAPTMEN1CYP1A2 | |
| SCHEMBL537876 | 0.85 | KDM4E (0.42) | ALDH1A1CYP2C19MAPTMEN1CYP1A2 | |
| SCHEMBL7347960 | 0.85 | ALDH1A1 (0.44) | ALDH1A1CYP2C19MAPTMEN1CYP1A2 | |
| SCHEMBL538225 | 0.85 | MAPT (0.42) | ALDH1A1MAPTMEN1CYP1A2KMT2A | |
| SCHEMBL7306658 | 0.85 | PDPK1 (0.42) | ALDH1A1MAPTMEN1KMT2ACLK1 | |
| SCHEMBL29896410 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CYP2C19MAPTMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598159-B2 | Therapeutic pyrazoloquinoline derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-12-03 | — | — | US | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2166852-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | ALDH1A1 587/4885CYP2C19 459/4885MAPT 461/4885 |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | ALDH1A1 587/4885CYP2C19 459/4885MAPT 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.